Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up
Introduction Currently, the majority of women worldwide with threatened preterm birth are treated with tocolytics. Although tocolytics can effectively delay birth for 48 hours, no tocolytic drug has convincingly been shown to improve neonatal outcomes and effects on long-term child development are u...
Saved in:
| Main Authors: | Martijn A Oudijk, Madelon van Wely, Eva Pajkrt, Job Klumper, Aleid G van Wassenaer-Leemhuis, Emilie V J van Limburg Stirum, Janneke Van 't Hooft, Larissa van der Windt |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-07-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/7/e083600.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Study protocol for a randomised trial for atosiban versus placebo in threatened preterm birth: the APOSTEL 8 study
by: Ben W Mol, et al.
Published: (2019-11-01) -
Correction: Study protocol for a randomised trial for atosiban versus placebo in threatened preterm birth: the APOSTEL 8 study
Published: (2022-10-01) -
The effectiveness and safety of continuous and repeated treatment of atosiban in twin pregnancy with threatened preterm labor: A propensity score-matched study.
by: Hao Zhu, et al.
Published: (2025-01-01) -
The effectiveness and safety of continuous and repeated treatment of atosiban in twin pregnancy with threatened preterm labor: A propensity score-matched study
by: Hao Zhu, et al.
Published: (2025-01-01) -
Seasonal patterns of preterm birth in the Netherlands: A population‐based cohort study
by: Annabelle L. vanGils, et al.
Published: (2025-07-01)